Publication

Effects of fluoxetine on human embryo development

Kaihola, H., Yaldir, F. G., Hreinsson, J., Hornaeus, K., Bergquist, J., Olivier, J. D. A., Akerud, H. & Sundstrom-Poromaa, I., 16-Jun-2016, In : Frontiers in cellular neuroscience. 10, 10 p., 160.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Kaihola, H., Yaldir, F. G., Hreinsson, J., Hornaeus, K., Bergquist, J., Olivier, J. D. A., ... Sundstrom-Poromaa, I. (2016). Effects of fluoxetine on human embryo development. Frontiers in cellular neuroscience, 10, [160]. https://doi.org/10.3389/fncel.2016.00160

Author

Kaihola, Helena ; Yaldir, Fatma G. ; Hreinsson, Julius ; Hornaeus, Katarina ; Bergquist, Jonas ; Olivier, Jocelien D. A. ; Akerud, Helena ; Sundstrom-Poromaa, Inger. / Effects of fluoxetine on human embryo development. In: Frontiers in cellular neuroscience. 2016 ; Vol. 10.

Harvard

Kaihola, H, Yaldir, FG, Hreinsson, J, Hornaeus, K, Bergquist, J, Olivier, JDA, Akerud, H & Sundstrom-Poromaa, I 2016, 'Effects of fluoxetine on human embryo development', Frontiers in cellular neuroscience, vol. 10, 160. https://doi.org/10.3389/fncel.2016.00160

Standard

Effects of fluoxetine on human embryo development. / Kaihola, Helena; Yaldir, Fatma G.; Hreinsson, Julius; Hornaeus, Katarina; Bergquist, Jonas; Olivier, Jocelien D. A.; Akerud, Helena; Sundstrom-Poromaa, Inger.

In: Frontiers in cellular neuroscience, Vol. 10, 160, 16.06.2016.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Kaihola H, Yaldir FG, Hreinsson J, Hornaeus K, Bergquist J, Olivier JDA et al. Effects of fluoxetine on human embryo development. Frontiers in cellular neuroscience. 2016 Jun 16;10. 160. https://doi.org/10.3389/fncel.2016.00160


BibTeX

@article{fcdf902116f14f9493aa6d2c5408fc16,
title = "Effects of fluoxetine on human embryo development",
abstract = "The use of antidepressant treatment during pregnancy is increasing, and selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed antidepressants in pregnant women. Serotonin plays a role in embryogenesis, and serotonin transporters are expressed in two-cell mouse embryos. Thus, the aim of the present study was to evaluate whether fluoxetine, one of the most prescribed SSRI antidepressant world-wide, exposure influences the timing of different embryo developmental stages, and furthermore, to analyze what protein, and protein networks, are affected by fluoxetine in the early embryo development. Human embryos (17 = 48) were randomly assigned to treatment with 0.25 or 0.5 IiM fluoxetine in culture medium. Embryo development was evaluated by time-lapse monitoring. The fluoxetine-induced human embryo proteome was analyzed by shotgun mass spectrometry. Protein secretion from fluoxetine-exposed human embryos was analyzed by use of high-multiplex immunoassay. The lower dose of fluoxetine had no influence on embryo development. A trend toward reduced time between thawing and start of cavitation was noted in embryos treated with 0.5 it M fluoxetine (p = 0.065). Protein analysis by shotgun mass spectrometry detected 45 proteins that were uniquely expressed in fluoxetine-treated embryos. These proteins are involved in cell growth, survival, proliferation, and inflammatory response. Culturing with 0.5 p M, but not 0.25 p M fluoxetine, caused a significant increase in urokinase-type plasminogen activator (uPA) in the culture medium. In conclusion, fluoxetine has marginal effects on the timing of developmental stages in embryos, but induces expression and secretion of several proteins in a manner that depends on dose. For these reasons, and in line with current guidelines, the lowest possible dose of SSRI should be used in pregnant women who need to continue treatment.",
keywords = "embryo development, selective serotonin reuptake inhibitors, serotonin, human, time-lapse monitoring, proteomics, secretomics, shotgun mass spectrometry, SEROTONIN REUPTAKE INHIBITORS, RESONANCE MASS-SPECTROMETRY, MATERNAL USE, ANTIDEPRESSANT USE, AMNIOTIC-FLUID, PREIMPLANTATION EMBRYOS, PLASMINOGEN-ACTIVATOR, ANTENATAL DEPRESSION, FOLLICULAR-FLUID, EARLY-PREGNANCY",
author = "Helena Kaihola and Yaldir, {Fatma G.} and Julius Hreinsson and Katarina Hornaeus and Jonas Bergquist and Olivier, {Jocelien D. A.} and Helena Akerud and Inger Sundstrom-Poromaa",
year = "2016",
month = "6",
day = "16",
doi = "10.3389/fncel.2016.00160",
language = "English",
volume = "10",
journal = "Frontiers in cellular neuroscience",
issn = "1662-5102",
publisher = "Frontiers Media SA",

}

RIS

TY - JOUR

T1 - Effects of fluoxetine on human embryo development

AU - Kaihola, Helena

AU - Yaldir, Fatma G.

AU - Hreinsson, Julius

AU - Hornaeus, Katarina

AU - Bergquist, Jonas

AU - Olivier, Jocelien D. A.

AU - Akerud, Helena

AU - Sundstrom-Poromaa, Inger

PY - 2016/6/16

Y1 - 2016/6/16

N2 - The use of antidepressant treatment during pregnancy is increasing, and selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed antidepressants in pregnant women. Serotonin plays a role in embryogenesis, and serotonin transporters are expressed in two-cell mouse embryos. Thus, the aim of the present study was to evaluate whether fluoxetine, one of the most prescribed SSRI antidepressant world-wide, exposure influences the timing of different embryo developmental stages, and furthermore, to analyze what protein, and protein networks, are affected by fluoxetine in the early embryo development. Human embryos (17 = 48) were randomly assigned to treatment with 0.25 or 0.5 IiM fluoxetine in culture medium. Embryo development was evaluated by time-lapse monitoring. The fluoxetine-induced human embryo proteome was analyzed by shotgun mass spectrometry. Protein secretion from fluoxetine-exposed human embryos was analyzed by use of high-multiplex immunoassay. The lower dose of fluoxetine had no influence on embryo development. A trend toward reduced time between thawing and start of cavitation was noted in embryos treated with 0.5 it M fluoxetine (p = 0.065). Protein analysis by shotgun mass spectrometry detected 45 proteins that were uniquely expressed in fluoxetine-treated embryos. These proteins are involved in cell growth, survival, proliferation, and inflammatory response. Culturing with 0.5 p M, but not 0.25 p M fluoxetine, caused a significant increase in urokinase-type plasminogen activator (uPA) in the culture medium. In conclusion, fluoxetine has marginal effects on the timing of developmental stages in embryos, but induces expression and secretion of several proteins in a manner that depends on dose. For these reasons, and in line with current guidelines, the lowest possible dose of SSRI should be used in pregnant women who need to continue treatment.

AB - The use of antidepressant treatment during pregnancy is increasing, and selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed antidepressants in pregnant women. Serotonin plays a role in embryogenesis, and serotonin transporters are expressed in two-cell mouse embryos. Thus, the aim of the present study was to evaluate whether fluoxetine, one of the most prescribed SSRI antidepressant world-wide, exposure influences the timing of different embryo developmental stages, and furthermore, to analyze what protein, and protein networks, are affected by fluoxetine in the early embryo development. Human embryos (17 = 48) were randomly assigned to treatment with 0.25 or 0.5 IiM fluoxetine in culture medium. Embryo development was evaluated by time-lapse monitoring. The fluoxetine-induced human embryo proteome was analyzed by shotgun mass spectrometry. Protein secretion from fluoxetine-exposed human embryos was analyzed by use of high-multiplex immunoassay. The lower dose of fluoxetine had no influence on embryo development. A trend toward reduced time between thawing and start of cavitation was noted in embryos treated with 0.5 it M fluoxetine (p = 0.065). Protein analysis by shotgun mass spectrometry detected 45 proteins that were uniquely expressed in fluoxetine-treated embryos. These proteins are involved in cell growth, survival, proliferation, and inflammatory response. Culturing with 0.5 p M, but not 0.25 p M fluoxetine, caused a significant increase in urokinase-type plasminogen activator (uPA) in the culture medium. In conclusion, fluoxetine has marginal effects on the timing of developmental stages in embryos, but induces expression and secretion of several proteins in a manner that depends on dose. For these reasons, and in line with current guidelines, the lowest possible dose of SSRI should be used in pregnant women who need to continue treatment.

KW - embryo development

KW - selective serotonin reuptake inhibitors

KW - serotonin

KW - human

KW - time-lapse monitoring

KW - proteomics

KW - secretomics

KW - shotgun mass spectrometry

KW - SEROTONIN REUPTAKE INHIBITORS

KW - RESONANCE MASS-SPECTROMETRY

KW - MATERNAL USE

KW - ANTIDEPRESSANT USE

KW - AMNIOTIC-FLUID

KW - PREIMPLANTATION EMBRYOS

KW - PLASMINOGEN-ACTIVATOR

KW - ANTENATAL DEPRESSION

KW - FOLLICULAR-FLUID

KW - EARLY-PREGNANCY

U2 - 10.3389/fncel.2016.00160

DO - 10.3389/fncel.2016.00160

M3 - Article

C2 - 27378857

VL - 10

JO - Frontiers in cellular neuroscience

JF - Frontiers in cellular neuroscience

SN - 1662-5102

M1 - 160

ER -

ID: 34370436